Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling

Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling

BackgroundAfatinib is mainly used to treat advanced non-small cell lung cancer, but its therapeutic effect on hepatocellular carcinoma is still unclear.MethodsOver 800 drugs were screened by CCK8 technology and afatinib was found to have a significant inhibitory effect on liver cancer cells. The exp...

Full description

Bibliographic Details
Main Authors: Chao Yu, Xinyi Zhang, Min Wang, Gaoxin Xu, Siqi Zhao, Yongheng Feng, Chao Pan, Weijun Yang, Jin Zhou, Longcheng Shang, Yong Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
afatinib
hepatocellular carcinoma (HCC)
PD-L1
immunotherapy
ERBB2
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1198118/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1198118/full

Similar Items